Adopted and Filed March 12, 2014
The following rules were approved during the March 12, 2014, meeting of the Board of Pharmacy.
- Chapter 4, "Pharmacist Interns." Pursuant to the authority of Iowa Code sections 147.76 and 155A.6, the Board of Pharmacy hereby amends Chapter 4, “Pharmacist-Interns,” Iowa Administrative Code. The amendments revise the requirements for pharmacist-intern registration, the number of hours required, and reporting of completed internship training. The Board has determined that the college-based training included in the college curriculum provides adequate prelicensure training and that requiring a pharmacist-intern to obtain additional training and credit outside the school year is not necessary. A student, prior to commencing internship training and experience, is required to register as a pharmacist-intern, and the Board and the Iowa colleges of pharmacy have agreed that, to ensure timely registration, a student must register at the beginning of the first professional year in the college of pharmacy. The amendments eliminate the requirements for completion and submission of the “internship booklet” certifying the competencies of the pharmacist-intern under the supervision of each pharmacist and, except for specific circumstances, eliminate the requirements relating to affidavits of internship training. The amendments also reorganize and clarify the internship requirements for foreign pharmacy graduate licensure candidates.
- Chapter 10, "Controlled Substances." Pursuant to the authority of Iowa Code section 124.201, the Board of Pharmacy hereby amends Chapter 10, “Controlled Substances,” Iowa Administrative Code. The amendments temporarily classify as Schedule I controlled substances four synthetic cannabinoids and ten synthetic cathinones in conformance with recent control of these same substances by the U. S. Department of Justice, Drug Enforcement Administration. The substances, commonly known as QUPIC, 5F-PB-22, AB-FUBINACA, ADB-PINACA, 4-MEC, 4-MEPPP, [alpha]-PVP, butylone, pentedrone, pentylone, flephedrone, 3-FMC, naphyrone, and [alpha]-PBP, have a high potential for abuse, have no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision.
Last Updated: April 10, 2014 9:55 AM